Art Bioscience is a pre-clinical biopharma company focused on finding genetic therapies for Duchenne muscular dystrophy (DMD) that meet the diversity and unmet needs of the patient through mRNA breaking through technological applications.

​

Our team of dedicated scientists are focusing on different forms of mRNA therapies, including protein replacement as well as gene editing.

​

Part of our mission is to utilize the versatility of mRNA replacement to implant an artificial, yet functional version of the Dystrophin protein, and translate the potential of gene editing into a broad class of differentiated and transformational medicines that can transform lives.

​

We are using our proprietary Lipid nanoparticles (LNPs) gene delivery system to muscles for effective delivery of our therapies to muscle cells.

​

LNPs are currently the most clinically advanced non-viral gene delivery systems.

​

Art Bioscience is leveraging solutions for rare diseases with breaking through science that is on the forefront of genetic medicine. Our platforms include: Gene Therapy, RNA Technologies, and Gene Editing. We are racing against time in finding an equitable suitable solution for all kids affected by DMD.